Copyright
©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Jan 27, 2022; 14(1): 209-223
Published online Jan 27, 2022. doi: 10.4254/wjh.v14.i1.209
Published online Jan 27, 2022. doi: 10.4254/wjh.v14.i1.209
Prognostic factors of survival and a new scoring system for liver resection of colorectal liver metastasis
Kai-Chi Cheng, Ada Sze-Man Yip, Department of Surgery, Kwong Wah Hospital, Hong Kong, China
Author contributions: Cheng KC designed the research study; Cheng KC and Yip ASM performed the research; Yip ASM analyzed the data and wrote the manuscript; all authors have read and approved the final manuscript.
Institutional review board statement: The protocol was approved by the Research Ethics Committee (Kowloon Central/Kowloon East) (Ref: KC/KC-21-0103/ER-1) in accordance with the laws and regulations (including Hong Kong laws), Hospital Authority policy, professional code of conduct, guidance of ICH GCP, and Declaration of Helsinki.
Informed consent statement: This study protocol was reviewed and approved by Hospital Authority Clinical Research Ethics Review Committee, reference number KCC/KEC-2021-0097. Written consent was not required as this is a retrospective study, and all data were retrospective. There was no prospective component to this study (i.e. patients were all anonymized, and there was no prospective follow-up). No patient was contacted for this study. All data were fully anonymized so that they cannot be traced back to an individual in this study.
Conflict-of-interest statement: The authors have no conflicts of interest to declare.
Data sharing statement: The datasets generated during and/or analyzed during the current study are not publicly available due to the potential that individual privacy could be compromised, but they are available in an anonymized form from the corresponding author upon reasonable request.
STROBE statement: The authors have read the STROBE Statement–checklist of items, and the manuscript was prepared and revised according to the STROBE Statement–checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Kai-Chi Cheng, FRCS (Ed), Doctor, Department of Surgery, Kwong Wah Hospital, No. 25 Waterloo Road, Kowloon, Hong Kong, China.
Received: October 7, 2021
Peer-review started: October 7, 2021
First decision: December 2, 2021
Revised: December 3, 2021
Accepted: December 23, 2021
Article in press: December 23, 2021
Published online: January 27, 2022
Processing time: 105 Days and 19.8 Hours
Peer-review started: October 7, 2021
First decision: December 2, 2021
Revised: December 3, 2021
Accepted: December 23, 2021
Article in press: December 23, 2021
Published online: January 27, 2022
Processing time: 105 Days and 19.8 Hours
Core Tip
Core Tip: Using multivariate analysis with the Cox model, we identified three criteria-number of liver metastases ≥ 5, size of the largest liver lesion ≥ 4 cm, and the presence of nodal metastasis from the primary tumor-for a new clinical scoring system. This new clinical score highly correlated with median overall survival and 5-year survival. We propose to use this score to formulate cancer-specific treatment for the patients. Priority over surgical resection should be given to the lowest score groups, and alternative oncological treatment should be considered in patients with the highest score.